| abstract |
Disclosed are cycloalkyl compounds of formula I wherein A is 1-naphthyl, salts and esters thereof, and methods for their preparation. Specific examples of compounds of formula I include: 3-((R)-1-naphthalen-1-yl-ethylamino)-cyclobutanecarboxylic acid, ((R)-1-Naphthalen-1-yl-ethyl)-{ 3-[3-(4-trifluoromethyl-phenyl)-[1,2,4]oxadiazol-5-yl]-cyclobutyl} -amine; hydrochloride, { [3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclobutanecarbonyl]-amino} -phenyl-acetic acid, 4-[3-((R)-1-naphthalen-1-yl-ethylamino)-cyclohexyl]-benzamidine, N-Benzyloxy-4-[3-((R)-1-naphthalen-1-yl-ethylamino)-cyclohexyl]-benzamide, and N-[3-(3-methoxyphenyl)cyclohexyl]-a-methyl-2-naphthalenemethanamine. Compounds of formula I are useful for treating physiological disorders or diseases associeated with disturbances of the calcium-sensing receptor (CaSR) activity, such as hyperparathyroidism. |